Sauer SM, Mitnick CD, Khan UT, Hewison CCH, Bastard M, et al.
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
BACKGROUND Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...
Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y, et al.
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...
Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, et al.
2023-04-28 • PLOS Global Public Health
2023-04-28 • PLOS Global Public Health
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb tr...
Gunasekera KS, Marcy O, Muñoz J, Lopez-Varela E, Sekadde MP, et al.
2023-03-13 • Lancet Child and Adolescent Health
2023-03-13 • Lancet Child and Adolescent Health
BACKGROUND Many children with pulmonary tuberculosis remain undiagnosed and untreated with related high morbidity and mortality. Recent advances in childhood tuberculosis algorithm d...
Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY, et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Siddiquea BN, Islam MS, Bam TS, Satyanarayana S, Enarson D, et al.
2013-09-21 • Public Health Action
2013-09-21 • Public Health Action
SETTING BRAC, a non-governmental organisation, implemented a modified smoking cessation programme for tuberculosis (TB) patients based on International Union Against Tuberculosis and...
Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S, et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...
Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M, et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...
Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N, et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
BACKGROUND Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...
Lachenal N, Hewison CCH, Berry C, Mitnick CD, Ahmed SM, et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION Drug-resistant tuberculosis (DR-TB) carries significant morbidity and mortality risk. Care of DR-TB in pregnancy is even more challenging. A recent meta-analysis examini...
Ahmed SM,
et al.
2022-06-10 • MSF Scientific Days International 2022
2022-06-10 • MSF Scientific Days International 2022
Lachenal N, Hewison CCH, Mitnick CD, Lomtadze N, Coutisson S, et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support of UNIT...
BACKGROUND Recent World Health Organisation guidance on drug-resistant tuberculosis treatment de-prioritised injectable agents, in use for decades, and endorsed all-oral longer regim...
